

N-Et FOSE alcohol

Teratology - 1c



HAZLETON

LABORATORIES AMERICA, INC.

2500 LEESEBURG TURNPIKE, VENTN, VIRGINIA 22180 USA

PROTOCOL

- | | |
|----------------------|--|
| 1. Study | Rat Teratology Study (Segment II) |
| 2. Purpose | To determine the embryo/fetal toxicity and teratogenic potential of a test material administered by gavage to pregnant rats during the period of fetal organogenesis. |
| 3. Test Material | |
| A. Identification | T-3352 |
| B. Purity | Assume 100% |
| C. Characteristics | Information on the methods of synthesis and stability, as well as data on composition or other characteristics which define the test material, are on file with the sponsor. |
| D. Reserve Samples | Reserve samples of the test and control articles will be taken at initiation and retained. These samples, as well as any remaining test material, will be returned to the sponsor upon issuance of the final report. |
| 4. Compliance | This study will be conducted in compliance with all Food and Drug Administration guidelines including the Good Laboratory Practice Regulations, <u>Federal Register</u> , December 22, 1978. |
| 5. Quality Assurance | The protocol, in-life phase, and the final report will be audited by the Office of Quality Assurance in accordance with standard operating procedures at Hazleton Laboratories. |

000452



HAZLETON

LABORATORIES AMERICA, INC.

4200 LEEESBURG TURNPIKE VIENNA VIRGINIA 22180 U.S.A. - 2 -

6. Experimental Design

A. Animals

- | | |
|--------------------|--|
| (1) Species | Rat |
| (2) Strain/Source | Sprague-Dawley CD®/Charles River Breeding Laboratories, Inc. |
| (3) Age at Receipt | Sexually mature, 8-10 weeks old (females) and 12-14 weeks old (males). Rats having clinical signs and/or body weight extremes will be culled prior to mating. |
| (4) Number/Sex | 100 females/100 males |
| (5) Identification | Individual eartags |
| (6) Husbandry | |
| (a) Housing | Individual housing, except during mating when one female is placed with one male, in hanging wire cages. |
| (b) Food | Purina Rodent Laboratory Chow® 5001, <u>ad libitum</u> . Sufficient quantities of food will be retained at study initiation to ensure that the same lot number of feed is available for the duration of the study. Feed is analyzed on a prospective basis for concentrations of specified heavy metals, antibiotics, aflatoxin, pesticides, and nitrosamines. |
| (c) Water | Tap water, <u>ad libitum</u> . The water is routinely analyzed on a retrospective basis for specified micro-organisms, pesticides, heavy metals, alkalinity, and halogens. |

000453



HAZLETON

LABORATORIES AMERICA, INC.

9200 LEESEBURY TURNPIKE VIRGINA VIRGINIA 22180 U.S.A.

- 3 -

(d) Contaminants

The study director and/or the sponsor have considered possible interfering substances potentially present in animal feed and water, including the test material itself or possible structurally related materials as well as the items listed in (b) and (c) above. None of these contaminants are reasonably expected to be present in animal feed or water at levels sufficient to interfere with this study.

(e) Environment

Every attempt will be made to maintain temperatures at $72 \pm 6^{\circ}\text{F}$ with a relative humidity of $50 \pm 20\%$. The project coordinator will be notified immediately if the room temperature exceeds a range of $50\text{-}90^{\circ}\text{F}$. A 12-hour light-dark cycle will be maintained.

(f) Quarantine

Minimum of two weeks.

(7) Randomization
Procedures

Upon observation of sperm or vaginal plug, the females will be assigned to experimental groups using a table of random numbers. All animals will be placed on treatment within a two-week period.

Prior to terminal sacrifice and cesarean section on day 20 of gestation, all surviving dams will be assigned random numbers so that all personnel performing cesarean sections and external, visceral, or skeletal examination of the fetuses will be unaware of the dose level from which the animals were derived. The numbers will be assigned by random card draw beginning with the first Group 1 animal and continuing numerically

000454



HAZLETON

LABORATORIES AMERICA, INC.

WOOD LEESEBURG TURNPIKE, LEVINA VIRGINIA 22180 U.S.A.

- 4 -

through Group 4. The order of cesarean sections on any given day will be determined by the random number assignment, beginning with the lowest code number and continuing through the highest for that day. This method will result in cesarean sections being performed in a random manner without knowledge of actual animal identity or dose level. Copies of the coded dam numbers will be forwarded to the project coordinator and to the sponsor by the group leader of the study.

Code numbers will be recorded on the prepartum examination records, fetal identification tags, visceral examination records, and skeletal examination records. Upon completion of all data collection and teratologic evaluations, the permanent animal identification and dose level assignments will be transcribed to all data records.

(8) Justification

Rats are sensitive to a number of agents which are known to be embryotoxic and/or teratogenic. Rats historically have been used in safety evaluation studies of this type and are required by the appropriate regulatory agencies. In addition, background teratology control data are available for rats of the proposed strain and source.

000455

**HAZLETON**

LABORATORIES AMERICA, INC.

3200 LEESSBURG TURNPIKE VIENNA VIRGINIA 22180 U.S.A.

- 5 -

B. Group Designation, Dose Levels, and Dosing Schedule

<u>Group No.</u>	<u>Dose Level*</u> mg/kg	<u>Dosing Schedule</u> Day of Gestation	<u>No. of Mated Female Rats</u>
1 (Control)	0	6-15	25
2 (Low)	1	6-15	25
3 (Mid)	10	6-15	25
4 (High)	30	6-15	25

*Based on individual body weights at each weighing interval during the dosing period. Dose levels will be determined upon review of the pilot teratology study data by the sponsor.

C. Dosing Procedures

- | | |
|---|--|
| (1) Method of Administration | The test material will be administered by oral intubation daily on Day 6 through Day 15 of gestation. The dose administered to each female will be based on the most recently recorded individual animal body weight during the dosing period and will be given at approximately the same time each day. |
| (2) Reason for Dosing Route | Oral intubation is used because of the relative ease of dosing and assurance of the dose amount. |
| (3) Preparation of Dosing Solutions/Suspensions | Solutions/suspensions of each concentration will be prepared fresh weekly in Duke's® corn oil. Vehicle and samples of each dosing solution should be shipped within 48 hours of preparation to: |

000456



HAZLETON

LABORATORIES AMERICA, INC.

2200 LEESSBURG TURNPIKE, ARLING, VIRGINIA 22180 U.S.A.

- 6 -

William C. McCormick, III
Toxicologist
Toxicology Services
Medical Dept./3M
220-2E 3M Center
St. Paul, MN 55101

Freezing is not required.

(4) Analysis of Dosing
Solutions/Suspensions

- | | |
|----------------------|---------------------------------|
| (a) Stability | To be conducted by the sponsor. |
| (b) Homogeneity | To be conducted by the sponsor. |
| (c) Routine Analyses | To be conducted by the sponsor. |

D. Mating Procedures

- | | |
|--------------------------|---|
| (1) Breeding | One male and one female will be placed in a breeding cage until a sufficient number of mated females is obtained (maximum breeding period is two weeks). |
| (2) Vaginal Examinations | During mating, daily vaginal examinations will be made for the presence and viability of sperm or the presence of a copulatory plug. Day of observation of sperm or plug is Day 0 of gestation. |
| (3) Disposition of Males | The males will be anesthetized, sacrificed, and discarded without necropsy upon completion of the mating. |

E. Observation of Animals (Dams)

- | | |
|------------------|---|
| (1) Observations | All animals will be examined twice daily for mortality and moribundity. |
|------------------|---|

000457



HAZLETON

LABORATORIES AMERICA, INC.

9200 LEESEBURG TURNPIKE, VIENNA, VIRGINIA 22180 U.S.A.

- 7 -

All animals will be observed once daily throughout gestation for clinical signs including time of onset, degree, and duration of effect. Cageside observations will include, but not be limited to, changes in skin and fur, eyes and mucous membranes, respiratory system, circulatory system, autonomic and central nervous system, somatomotor activity, and behavior.

In addition, careful clinical observations will be made at each weighing interval.

Signs will be recorded as they are observed.

(2) Body Weights

Animals will be weighed on Days 0, 6, 8, 12, 16, and 20 of gestation.

(3) Food Consumption

A measured quantity of food will be provided on gestation day 0, and food consumption will be measured on gestation days 6, 8, 12, 16, and 20. Any food added during the gestation intervals will be recorded.

F. Termination

(1) Sick/Moribund/Found
Dead Dams

Dams found dead or sacrificed because of sickness or moribundity will be examined for any grossly abnormal thoracic, abdominal, or pelvic viscera. No abnormal viscera will be retained unless requested by the sponsor. Uteri and ovaries will be examined for implantations and corpora lutea, respectively.

Findings will be recorded.

000458



HAZLETON

LABORATORIES AMERICA, INC.

9200 LEESEBURG TURNPIKE, FARMINGDALE, VIRGINIA 22185 U.S.A.

- 8 -

(2) Dams Showing Signs
of Abortion or
Premature Delivery

Dams exhibiting these signs will be sacrificed by carbon dioxide inhalation. Any grossly abnormal thoracic, abdominal, or pelvic viscera will be noted. No abnormal viscera will be retained unless requested by the sponsor. Uteri and ovaries will be examined for implantations and corpora lutea, respectively.

Findings will be recorded.

(3) Terminal Sacrifice

On Day 20 of gestation, all surviving dams will be weighed and sacrificed by carbon dioxide inhalation. The fetuses will be taken immediately by cesarean section, see Section G.(1) below.

G. Postmortem Procedures

(1) Cesarean Section

A cesarean section will be performed on those females sacrificed on Day 20 of gestation. Any grossly abnormal thoracic, abdominal, or pelvic viscera will be noted. No abnormal viscera will be saved unless requested by the sponsor.

The uterus from each female will be excised, weighed, and examined for the number and placement of uterine implantation sites, number of live and dead fetuses, number of early and late resorbing fetuses, and any abnormalities. The uterus will not be reweighed after the contents have been removed. The ovaries will be examined for the number of corpora lutea.

Findings will be recorded.

(2) Fetal Evaluations

Each fetus will be sexed, weighed, examined for external abnormalities, and identified with a tag.

000459



- 9 -

Approximately one-third of all live fetuses from each litter will be selected and processed for visceral examination by the Wilson Technique for assessing soft tissue development. During visceral examination of the fetuses, particular attention will be paid to the examination of the eyes (size, lens, and retina), palate, and brain (third and lateral ventricles). Stainless steel razor blades will be used for sectioning procedures. Abnormalities will be described as anomalies or variants.

The remaining fetuses will be eviscerated and processed for skeletal examination using the Alizarin Red S staining method. This evaluation will include examination of the skull, long bones, vertebral column, rib cage, extremities, and pectoral and pelvic girdles. Bone alignment and degree of ossification will be assessed. Abnormalities will be described as anomalies or variants.

Fetuses will be selected for visceral or skeletal examination in the following manner:

Beginning at the ovarian end of the left uterine horn and continuing past the cervix into the right uterine horn, the first available fetus will be fixed in Bouin's solution for visceral evaluation. The next two fetuses will be processed for skeletal evaluation. This sequence will be repeated until all available fetuses have been selected.

Dead fetuses will be discarded without examination.

(3) Tissue Preservation

The following tissues from each dam will be preserved in 10% neutral buffered formalin:

ovaries uterus

All fetuses will be retained in alcohol, Bouin's fixative, or glycerine.

000460



HAZLETON

LABORATORIES AMERICA, INC

5200 LEESEBURG TURNPIKE VIENNA VIRGINIA 22180 U.S.A

- 10 -

7. Final Report

At termination of the study, a final report which includes the following information will be prepared and submitted:

A. Experimental Design and Methods

B. Results

- (1) Maternal Data - Arranged by test group and supplied in tabular form.

(a) Data for each animal showing:

identification number	food consumption at each interval
disposition (pregnancy status and day of cesarean section or sacrifice)	body weight at each weighing interval
	daily clinical signs

(b) Data for each dose level showing:

number of animals placed on study	mean body weight change for gestation days 0-6, 6-8, 6-16, 16-20, 0-20, and 6-20
number and percent pregnant	mean food consumption at each interval
number and percent surviving to cesarean section on gestation day 20	mean terminal body weight (individual terminal body weights minus gravid uterine weights)
number and percent that aborted (including premature delivery)	mean uterine weights
mean body weight at each weighing interval	summary incidence of clinical signs
	summary incidence of gross pathology

- (2) Fetal Data - Arranged by test group and supplied in tabular form.

(a) Data for each litter showing:

identification number	number and percent of late resorbing fetuses
number and percent of live fetuses	number and percent of total resorbing fetuses
number of each sex	

000461



HAZLETON

LABORATORIES AMERICA, INC.

2500 LEESEBURG TURNPIKE, VENTNOR, PENNSYLVANIA 19008 U.S.A.

- 11 -

mean live fetal	number of corpora lutea
weight by sex	number of implantations
number and percent	implantation efficiency
of dead fetuses	$\frac{(\text{implantations}}{\text{corpora lutea}} \times 100$
number and percent of	
early resorbing fetuses	

(b) Abnormality data for each litter showing:

- identification number
- number of fetuses examined for external abnormalities;
 - number of fetuses within normal limits
 - number of fetuses with a particular external variant
 - number of fetuses with a particular external anomaly
- number of fetuses examined for skeletal abnormalities;
 - number of fetuses within normal limits
 - number of fetuses with a particular skeletal variant
 - number of fetuses with a particular skeletal anomaly
- number of fetuses examined for visceral abnormalities;
 - number of fetuses within normal limits
 - number of fetuses with a particular visceral variant
 - number of fetuses with a particular visceral anomaly
- incidence and description of each type of abnormality

(c) Cumulative data for each dose level showing:

- identification of each group
- number of litters examined
- mean number and percent of live fetuses
- mean weight of live fetuses by sex
- mean fetal viability
 - $\frac{(\text{live fetuses}}{\text{implantations}} \times 100$
- mean number and percent of dead fetuses
- mean number and percent of early resorbing fetuses
- mean number and percent of late resorbing fetuses
- mean number and percent of total resorbing fetuses
- mean number of corpora lutea
- mean number of implantations
- mean implantation efficiency
- number and percent of litters with any external variant
- number and percent of litters with any external anomaly
- number and percent of litters with a particular
 - external variant
- number and percent of litters with a particular
 - external anomaly

000462



HAZLETON

LABORATORIES AMERICA, INC.

9200 LEESEBURG TURNPIKE, DENVER, VIRGINIA 22180 USA

- 12 -

number and percent of litters with any skeletal variant
number and percent of litters with any skeletal anomaly
number and percent of litters with a particular
skeletal variant
number and percent of litters with a particular
skeletal anomaly
number and percent of litters with any visceral variant
number and percent of litters with any visceral anomaly
number and percent of litters with a particular
visceral variant
number and percent of litters with a particular
visceral anomaly
number and percent of litters with any variant
number and percent of litters with any anomaly

C. Statistical Analyses

The significance of suggestive intergroup difference will be tested using appropriate statistical tests.

Body weight changes and total food consumption of pregnant animals during the treatment and post-treatment phases will be analyzed by one-way ANOVA and fetal weights will be analyzed by one-way ANCOVA. If appropriate, Dunnett's t-test will be performed to identify groups with significantly different means from the control. Heterogeneous data, as determined by Levene's test, will undergo a series of transformations to achieve homogeneity of variances prior to performing the above analyses.

Kruskal-Wallis' nonparametric one-way ANOVA or a modified Fisher-Erwin Exact Test, depending on the nature of the data, will be performed on incidence data. In addition, a nonparametric test for trend will be performed on these data. Incidence data to be analyzed include the following:

- (1) Percent males/litter
- (2) Percent fetal viability
- (3) Percent resorptions
- (4) Percent of total fetuses examined with a particular external, visceral, or skeletal anomaly or variant

000463



HAZLETON

LABORATORIES AMERICA, INC.

5200 LEESBURG TURNPIKE VIENNA VIRGINIA 22180 USA

- 13 -

- (5) Percent of total litters examined with a particular anomaly or variant (external, visceral, or skeletal)
- (6) Percent of total fetuses examined with any anomaly or variant
- (7) Percent of total litters examined with any anomaly or variant

All tests for significance are made at the 5.0% probability level, two-tailed for the group comparisons and one-tailed for Levene's F-tests and trend analysis.

The final report, or a draft copy of such, will be reviewed by the sponsor within three months of receipt. Any revisions or comments will be submitted to Hazleton within this period.

5089B
6/2/83

000464